C4 Therapeutics, Inc. Comprehensive Income
C4 Therapeutics, Inc. (CCCC) reported Comprehensive Income of -$23.76 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$23.76M.
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$25.50M.
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$20.58M.
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$32.05M.
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$105.00M.
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$105.14M.
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$128.48M.
- C4 Therapeutics, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$131.54M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$23.76M 10-Q · filed 2026-08-11 | -$49.26M 10-Q · filed 2026-08-11 | -$69.83M derived: sum of 3 quarters · filed 2026-08-11 | -$101.88M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$25.50M 10-Q · filed 2026-05-12 | -$46.08M derived: sum of 2 quarters · filed 2026-05-12 | -$78.13M derived: sum of 3 quarters · filed 2026-05-12 | -$104.22M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$20.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$52.63M derived: sum of 2 quarters · filed 2026-02-26 | -$78.72M derived: sum of 3 quarters · filed 2026-08-11 | -$105.00M 10-K · filed 2026-02-26 | |
| 2025-09-30 | -$32.05M 10-Q · filed 2025-11-06 | -$58.14M derived: sum of 2 quarters · filed 2026-08-11 | -$84.42M 10-Q · filed 2025-11-06 | -$119.45M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$26.09M 10-Q · filed 2026-08-11 | -$52.42M 10-Q · filed 2026-08-11 | -$87.40M derived: sum of 3 quarters · filed 2026-08-11 | -$111.17M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$26.33M 10-Q · filed 2026-05-12 | -$61.31M derived: sum of 2 quarters · filed 2026-05-12 | -$85.08M derived: sum of 3 quarters · filed 2026-05-12 | -$102.85M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | -$34.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$58.75M derived: sum of 2 quarters · filed 2026-02-26 | -$76.52M derived: sum of 3 quarters · filed 2026-02-26 | -$105.14M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$23.77M 10-Q · filed 2025-11-06 | -$41.55M derived: sum of 2 quarters · filed 2025-11-06 | -$70.16M 10-Q · filed 2025-11-06 | -$104.14M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | -$17.78M 10-Q · filed 2025-08-07 | -$46.39M 10-Q · filed 2025-08-07 | -$80.37M derived: sum of 3 quarters · filed 2025-08-07 | -$106.53M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$28.61M 10-Q · filed 2025-05-07 | -$62.59M derived: sum of 2 quarters · filed 2025-05-07 | -$88.76M derived: sum of 3 quarters · filed 2025-05-07 | -$123.98M derived: sum of 4 quarters · filed 2025-05-07 | |
| 2023-12-31 | -$33.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$60.14M derived: sum of 2 quarters · filed 2025-02-27 | -$95.37M derived: sum of 3 quarters · filed 2025-02-27 | -$128.48M 10-K · filed 2025-02-27 | |
| 2023-09-30 | -$26.17M 10-Q · filed 2024-10-31 | -$61.39M derived: sum of 2 quarters · filed 2024-10-31 | -$94.51M 10-Q · filed 2024-10-31 | -$130.42M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | -$35.23M 10-Q · filed 2024-08-01 | -$68.34M 10-Q · filed 2024-08-01 | -$104.25M derived: sum of 3 quarters · filed 2024-08-01 | -$137.04M derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | -$33.11M 10-Q · filed 2024-05-08 | -$69.03M derived: sum of 2 quarters · filed 2024-05-08 | -$101.81M derived: sum of 3 quarters · filed 2024-05-08 | -$130.16M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$35.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$68.70M derived: sum of 2 quarters · filed 2024-02-22 | -$97.04M derived: sum of 3 quarters · filed 2024-02-22 | -$131.54M 10-K · filed 2024-02-22 | |
| 2022-09-30 | -$32.79M 10-Q · filed 2023-11-01 | -$61.13M derived: sum of 2 quarters · filed 2023-11-01 | -$95.62M 10-Q · filed 2023-11-01 | -$111.90M derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | -$28.34M 10-Q · filed 2023-08-08 | -$62.84M 10-Q · filed 2023-08-08 | -$79.12M derived: sum of 3 quarters · filed 2023-08-08 | -$103.89M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$34.49M 10-Q · filed 2023-05-04 | -$50.77M derived: sum of 2 quarters · filed 2023-05-04 | -$75.54M derived: sum of 3 quarters · filed 2023-05-04 | -$98.10M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | -$16.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$41.05M derived: sum of 2 quarters · filed 2023-02-23 | -$63.60M derived: sum of 3 quarters · filed 2023-02-23 | -$84.68M 10-K · filed 2023-02-23 | |
| 2021-09-30 | -$24.77M 10-Q · filed 2022-11-03 | -$47.32M derived: sum of 2 quarters · filed 2022-11-03 | -$68.40M 10-Q · filed 2022-11-03 | -$90.19M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | -$22.55M 10-Q · filed 2022-08-04 | -$43.63M 10-Q · filed 2022-08-04 | -$65.42M derived: sum of 3 quarters · filed 2022-08-04 | -$87.25M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$21.08M 10-Q · filed 2022-05-05 | -$42.87M derived: sum of 2 quarters · filed 2022-05-05 | -$64.69M derived: sum of 3 quarters · filed 2022-05-05 | -$75.49M derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | -$21.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$43.62M derived: sum of 2 quarters · filed 2022-02-24 | -$54.41M derived: sum of 3 quarters · filed 2022-02-24 | -$66.32M 10-K · filed 2022-02-24 | |
| 2020-09-30 | -$21.82M 10-Q · filed 2021-11-10 | -$21.84M 10-Q · filed 2020-11-12 | -$32.62M derived: sum of 2 quarters · filed 2021-11-10 | -$44.53M 10-Q · filed 2021-11-10 | -$54.55M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$10.79M 10-Q · filed 2021-08-11 | -$22.71M 10-Q · filed 2021-08-11 | -$32.73M derived: sum of 3 quarters · filed 2022-02-24 | -$42.81M derived: sum of 4 quarters · filed 2022-02-24 | |
| 2020-03-31 | -$11.91M 10-Q · filed 2021-05-13 | -$21.93M derived: sum of 2 quarters · filed 2022-02-24 | -$32.02M derived: sum of 3 quarters · filed 2022-02-24 | ||
| 2019-12-31 | -$10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$20.11M derived: sum of 2 quarters · filed 2022-02-24 | -$34.10M 10-K · filed 2022-02-24 | ||
| 2019-09-30 | -$10.09M 10-Q · filed 2020-11-12 | -$24.08M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |